NEW YORK (GenomeWeb News) – GNS Healthcare today announced a two-year agreement with Brigham and Women's Hospital to identify biomarkers that may be able to identify patient response to asthma therapies.
The partners will also seek to discover new biology for more effective treatments.
The collaboration brings together the partners' computational expertise and combines it with BWH's disease expertise and GNS' supercomputer-driven Reverse Engineering Forward Simulation scientific computing platform, they said in a statement.
De-identified data from more than 700 participants in the Childhood Asthma Management Program, a five-year clinical trial, will be used in the project announced today. Data from CAMP include genetics, gene expression, several clinical and environmental measures, and clinical outcomes, such as hospitalizations, requirements for fast-acting asthma drugs, and reduced lung growth.
BWH and GNS will use the data and the REFS platform to build computer models that connect genetics to biology to clinical outcomes. The computer models will be simulated to study the "key genetic and molecular drivers of both childhood asthma disease progression and response to inhaled corticosteroids," BWH and GNS said.
Financial terms of the deal were not disclosed.
Based in Cambridge, Mass., GNS is a subsidiary of healthcare IT firm Via Science and mines data to gain insight into diseases and drug responses.